RESUMEN
INTRODUCTION: Multiple endocrine neoplasia (MEN) syndromes are a group of hereditary cancer syndromes that can predispose children to endocrine neoplasms developing within the head and neck. OBJECTIVE: To examine the neoplastic manifestations of MEN type 1 (MEN1) and MEN type 2 (MEN2) in the pediatric head and neck. METHODS: Single-institution, retrospective review of pediatric MEN between 2005 and 2022. RESULTS: Fifty-three children were genetically confirmed with MEN (15 MEN1, 34 MEN2A, and 4 MEN2B), while three patients received clinical diagnoses of MEN1. The male to female ratio was essentially equal (1.15:1), and a documented family history of cancer was present in 89% (50/56). After multidisciplinary evaluation, a familial MEN diagnosis was confirmed in 91% (51/56). The mean ages of initial presentation and surgical intervention were 8.9 years (SD 5) and 9.8 years (SD 4.8), respectively. Although patients with MEN2 received surgery earlier than patients with MEN1 (8.7 vs 12.7 years), surgical patients with MEN2 in this cohort were older relative to current American Thyroid Association (ATA) guidelines primarily due to late presentation. Thyroid malignancies were identified in 36% (9/25) of thyroidectomy specimens (21 MEN2A, 4 MEN2B), with medullary thyroid carcinoma (MTC) present in five MEN2A patients and three MEN2B patients (89%), and papillary thyroid carcinoma (PTC) present in one MEN2A patient (11%). Nearly 90% (8/9) of thyroid malignancies were occult, with some occurring earlier than predicted by current guidelines (ATA-MOD and ATA-H). Central neck dissections were performed in 24% (2 MEN1, 2 MEN2A, and 4 MEN2B), with two MEN2B (50%) demonstrating cervical lymph node (LN) metastases. Additional histopathologic findings included C-cell hyperplasia in 57% (12/21) of MEN2A thyroidectomy patients. Of the eight MEN1 parathyroidectomy patients, four demonstrated parathyroid hyperplasia and four presented with parathyroid adenoma. CONCLUSION: Nearly 60% required head and neck procedures. While MEN1 guidelines were appropriate for our cohort, we identified patients with MEN2 that developed MTC earlier than expected based on current ATA guidelines, including children in categories considered lower risk. In conjunction with a multidisciplinary approach, pediatric head and neck surgeons should be aware of the potential need for earlier surgical intervention in the pediatric MEN2 population.
Asunto(s)
Neoplasia Endocrina Múltiple Tipo 2a , Neoplasia Endocrina Múltiple Tipo 2b , Neoplasia Endocrina Múltiple , Neoplasias de la Tiroides , Humanos , Niño , Femenino , Masculino , Neoplasia Endocrina Múltiple Tipo 2a/complicaciones , Neoplasia Endocrina Múltiple Tipo 2b/complicaciones , Neoplasia Endocrina Múltiple Tipo 2b/diagnóstico , Hiperplasia , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple/genética , Neoplasias de la Tiroides/diagnóstico , Neoplasias de la Tiroides/epidemiología , Neoplasias de la Tiroides/cirugíaRESUMEN
OBJECTIVE: Accurate demarcation between multiple endocrine neoplasia, type 1 (MEN1)- related primary hyperparathyroidism (MPHPT) and sporadic PHPT (SPHPT) is important to plan the management of primary parathyroid disease and surveillance for other endocrine and nonendocrine tumours. The objective of this study is to compare the clinical, biochemical and radiological features and surgical outcomes in patients with MPHPT versus SPHPT and to identify the predictors of MEN1 syndrome in PHPT. DESIGN, PATIENTS AND MEASUREMENTS: This was an ambispective observationalstudy involving 251 patients with SPHPT and 23 patients with MPHPT evaluated at the endocrine clinic of All India Institute of Medical Sciences, New Delhi, India between January 2015 and December 2021. RESULTS: The prevalence of MEN1 syndrome among patients with PHPT was 8.2% and a genetic mutation was identified by Sanger sequencing in 26.1% of patients with MPHPT. Patients with MPHPT were younger (p < .001), had lower mean serum calcium (p = .01) and alkaline phosphatase (ALP; p = .03) levels and lower bone mineral density (BMD) Z score at lumbar spine (p < .001) and femoral neck (p = .007). The prevalence of renal stones (p = .03) and their complications (p = .006) was significantly higher in MPHPT group. On multivariable analysis, factors predictive of MPHPT were hyperplasia on histopathology [OR 40.1, p < .001], ALP levels within reference range [OR 5.6, p = .02] and lumbar spine BMD [OR 0.39 per unit increase in Z score, p < .001]. CONCLUSIONS: Patients with MPHPT have more severe, frequent and early onset of bone and renal involvement despite milder biochemical features. A normal serum ALP, low BMD for age and gender at lumbar spine and histopathology evidence of hyperplasia are predictive factors for MEN1 syndrome in PHPT.
Asunto(s)
Hiperparatiroidismo Primario , Neoplasia Endocrina Múltiple Tipo 1 , Neoplasia Endocrina Múltiple , Humanos , Hiperparatiroidismo Primario/complicaciones , Hiperparatiroidismo Primario/cirugía , Hiperplasia/complicaciones , Neoplasia Endocrina Múltiple Tipo 1/complicaciones , Neoplasia Endocrina Múltiple Tipo 1/patología , Neoplasia Endocrina Múltiple/complicaciones , Resultado del Tratamiento , Densidad ÓseaRESUMEN
ABSTRACT: Multiple endocrine neoplasia 1 (MEN1) syndrome is an autosomal dominant syndrome comprising a triad of pancreatic, pituitary, and parathyroid tumors. Adrenal cortical carcinoma occurs rarely in MEN1 syndrome. Here, we have presented a case of a 62-year-old woman with adrenal mass and elevated serum parathormone levels, who underwent 68Ga-DOTANOC PET/CT. 68Ga-DOTANOC PET/CT showed intense tracer concentration in the left adrenal mass and lesions in the liver, pancreas, and peritoneum. Biopsy of the peritoneal deposit revealed metastatic adrenocortical carcinoma, and further genetic testing showed MEN1 mutation.
Asunto(s)
Neoplasias de la Corteza Suprarrenal , Carcinoma Corticosuprarrenal , Neoplasia Endocrina Múltiple Tipo 1 , Neoplasia Endocrina Múltiple , Neoplasias de la Corteza Suprarrenal/complicaciones , Neoplasias de la Corteza Suprarrenal/diagnóstico por imagen , Carcinoma Corticosuprarrenal/complicaciones , Carcinoma Corticosuprarrenal/diagnóstico por imagen , Femenino , Humanos , Persona de Mediana Edad , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple Tipo 1/complicaciones , Neoplasia Endocrina Múltiple Tipo 1/diagnóstico por imagen , Compuestos Organometálicos , Tomografía Computarizada por Tomografía de Emisión de PositronesRESUMEN
The 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) held in Houston, TX, USA, focused on emerging topics in the pathogenesis and therapy of malignant endocrine tumors associated with MEN syndromes. With MEN-2 syndromes, the most common malignancy is medullary thyroid carcinoma (MTC). In the spirit of the original MEN meeting workshop model, the conference included didactic lectures and interactive working groups of clinicians and researchers focused on the state of science in MTC and ongoing challenges or unmet needs in the understanding of MTC and to develop strategies to address these issues.
Asunto(s)
Carcinoma Neuroendocrino/etiología , Neoplasia Endocrina Múltiple/complicaciones , Neoplasias de la Tiroides/etiología , Carcinoma Neuroendocrino/patología , Humanos , Neoplasias de la Tiroides/patologíaRESUMEN
Autoimmune Addison's disease (AAD) is a rare condition occurring either in isolation or associated with other autoimmune diseases as part of an autoimmune polyglandular syndrome (APS) type 1, 2 or 4. Multiple endocrine neoplasia (MEN) type 1, 2 or 4 is a hereditary autosomal dominant cancer syndrome. Medullary thyroid carcinoma and pheochromocytoma are neoplasms common to MEN-2a and MEN-2b. We describe a unique, complex case of a man resulted affected by both APS-2 and MEN-2a. The patient developed Hashimoto's thyroiditis, diabetes mellitus type 1 and AAD, despite testing negative for adrenal cortex autoantibodies (ACA) and steroid 21-hydroxylase autoantibodies (21-OHAb). Moreover, he had also a family history for MEN-2a and he first developed medullay thyroid cancer, then bilateral pheochromocytoma on the adrenal substrate of an AAD. On adrenal histology we found complete bilateral cortical atrophy in the presence of a lymphocytic infiltration and fibrosis, confirming an ACA and 21-OHAb-negative AAD. This datum is the first documented in a living individual and confirms that the absence of autoantibodies is not incompatible with an autoimmune disease and confirms that AAD is a cell-mediated autoimmune disease limited to the adrenal cortex and sparing medullary. In the light of a literature review concerning the association between APS and MEN, this is the first proven case to be reported in humans. Finally, our findings suggest that adrenal medullary tumor can develop even on an adrenal gland with cortical atrophy due to autoimmune adrenalitis.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/complicaciones , Neoplasia Endocrina Múltiple/complicaciones , Feocromocitoma/complicaciones , Poliendocrinopatías Autoinmunes/complicaciones , Neoplasias de las Glándulas Suprarrenales/inmunología , Adulto , Humanos , Masculino , Neoplasia Endocrina Múltiple/inmunología , Linaje , Feocromocitoma/inmunología , Poliendocrinopatías Autoinmunes/inmunologíaAsunto(s)
Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Enfermedades del Sistema Inmune/genética , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple/genética , Adenoma/complicaciones , Adenoma/genética , Adenoma/patología , Anciano , Femenino , Humanos , Hiperprolactinemia/complicaciones , Hiperprolactinemia/genética , Hiperprolactinemia/patología , Enfermedades del Sistema Inmune/etiología , Neoplasia Endocrina Múltiple/diagnóstico , Neoplasia Endocrina Múltiple/patología , Neoplasias de las Paratiroides/complicaciones , Neoplasias de las Paratiroides/genética , Neoplasias de las Paratiroides/patología , Fenotipo , Neoplasias Hipofisarias/complicaciones , Neoplasias Hipofisarias/genética , Neoplasias Hipofisarias/patologíaRESUMEN
This report summarizes published data on parathyroid cancer, with the inclusion of topics discussed at MEN2019: 16th International Workshop on Multiple Endocrine Neoplasia, 27-29 March 2019, Houston, TX, USA. An expert panel on parathyroid cancer was constituted by the Steering Committee to address key questions in the field. The objectives were to recap open forum discussion of interested parties from multiple disciplines. The expert panel met in a closed session to consult on the data to be highlighted on the evidence-based results and on the future directions. Preceding the Conference, members of the expert panel conducted an extensive literature search. All presentations were based upon the best peer-reviewed information taking into account the historical and current literature. Questions were developed by the expert panel on parathyroid carcinoma. A comprehensive literature search for relevant studies was undertaken. This report represents the expert panel's synthesis of the conference material placed in a context designed to be relevant to clinicians and those engaged in cutting-edge studies of parathyroid carcinoma. This document not only provides a summary of our current knowledge but also places recent advances in its management into a context that should enhance future advances in our understanding of parathyroid carcinoma.
Asunto(s)
Neoplasia Endocrina Múltiple/complicaciones , Neoplasias de las Paratiroides/etiología , Humanos , Neoplasias de las Paratiroides/patologíaRESUMEN
CONTEXT: Germline loss-of-function CDKN1B gene variants cause the autosomal dominant syndrome of multiple endocrine neoplasia type 4 (MEN4). Even though pituitary neuroendocrine tumors are a well-known component of the syndrome, only 2 cases of Cushing's disease (CD) have so far been described in this setting. AIM: To screen a large cohort of CD patients for CDKN1B gene defects and to determine their functional effects. PATIENTS: We screened 211 CD patients (94.3% pediatric) by germline whole-exome sequencing (WES) only (n = 157), germline and tumor WES (n = 27), Sanger sequencing (n = 6), and/or germline copy number variant (CNV) analysis (n = 194). Sixty cases were previously unpublished. Variant segregation was investigated in the patients' families, and putative pathogenic variants were functionally characterized. RESULTS: Five variants of interest were found in 1 patient each: 1 truncating (p.Q107Rfs*12) and 4 nontruncating variants, including 3 missense changes affecting the CDKN1B protein scatter domain (p.I119T, p.E126Q, and p.D136G) and one 5' untranslated region (UTR) deletion (c.-29_-26delAGAG). No CNVs were found. All cases presented early (10.5 ± 1.3 years) and apparently sporadically. Aside from colon adenocarcinoma in 1 carrier, no additional neoplasms were detected in the probands or their families. In vitro assays demonstrated protein instability and disruption of the scatter domain of CDKN1B for all variants tested. CONCLUSIONS: Five patients with CD and germline CDKN1B variants of uncertain significance (n = 2) or pathogenic/likely pathogenic (n = 3) were identified, accounting for 2.6% of the patients screened. Our finding that germline CDKN1B loss-of-function may present as apparently sporadic, isolated pediatric CD has important implications for clinical screening and genetic counselling.
Asunto(s)
Biomarcadores/análisis , Síndrome de Cushing/etiología , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Variaciones en el Número de Copia de ADN , Mutación de Línea Germinal , Neoplasia Endocrina Múltiple/complicaciones , Adolescente , Adulto , Niño , Síndrome de Cushing/patología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Neoplasia Endocrina Múltiple/genética , Neoplasia Endocrina Múltiple/patología , Fenotipo , Pronóstico , Adulto JovenRESUMEN
Multiple Endocrine Neoplasia (MEN) type 4 is a rare genetic condition that results from variants of the CDKN1B gene and predisposes individuals to develop endocrine tumors. Spinal neurofibromatosis (SNF) is an uncommon subtype of neurofibromatosis type 1 (NF1) characterized by bilateral neurofibromas of all spinal roots. Here we report a case of the co-occurrence of these syndromes, which has not yet been described in the literature. A male in his 60s presented with Gleason 5 + 4 localized prostate adenocarcinoma treated with radical prostatectomy. Two years later, he developed liver and bone metastasis consistent with trans-differentiation into small cell carcinoma. He developed hypercalcemia due to primary hyperparathyroidism from a parathyroid adenoma treated surgically. His family history was significant for a first-degree relative with a clinical diagnosis of NF1 and several second-degree relatives with multiple café-au-lait macules. Spine MRI showed multiple bilateral neurofibromas. Germline genetic testing showed a pathogenic variant in the CDKN1B gene, a variant in the NF1 gene, and a normal MEN1 gene. In this rare case of MEN4 and SNF, the patient was asymptomatic for much of his life. In addition to parathyroid adenoma and spinal neurofibromas, he had prostate adenocarcinoma with trans-differentiation into metastatic small cell cancer. Whether this diagnosis was coincidental or related to an emerging phenotype remains to be elucidated.
Asunto(s)
Neoplasia Endocrina Múltiple/complicaciones , Neurofibromatosis 1/complicaciones , Neoplasias de la Columna Vertebral/complicaciones , Adenocarcinoma/complicaciones , Adenocarcinoma/patología , Adenoma/complicaciones , Inhibidor p27 de las Quinasas Dependientes de la Ciclina/genética , Familia , Pruebas Genéticas , Humanos , Hiperparatiroidismo/etiología , Masculino , Persona de Mediana Edad , Neoplasia Endocrina Múltiple/genética , Neurofibromatosis 1/diagnóstico por imagen , Neoplasias de las Paratiroides/complicaciones , Neoplasias de la Próstata/complicaciones , Neoplasias de la Próstata/patología , Neoplasias de la Columna Vertebral/diagnóstico por imagenRESUMEN
About 5% of gastroenteropancreatic and thoracic neuroendocrine neoplasms (NENs) arise in the context of an inherited tumour syndrome. The two most frequent syndromes are: multiple endocrine neoplasia type 1 (MEN1), associated with a large spectrum of endocrine and non endocrine tumours, including duodenopancreatic, thymic and bronchial NENs, and the von Hippel-Lindau syndrome VHL, associated with pancreatic NENs. Two inherited syndromes have a low incidence of NENs: neurofibromatosis type 1 (NF1), associated with duodenal somatostatinomas, and tuberous sclerosis (TSC), associated with pancreatic NENs. Two rare syndromes have a high incidence of NENs: multiple endocrine neoplasia type 4 (MEN4), with a tumour spectrum similar to that of MEN1, and glucagon cell hyperplasia neoplasia (GCHN), involving only the pancreas. It is likely that other syndromes remain to be characterized, especially in familial small-intestinal NENs. The diagnosis is usually raised because of the suggestive clinical setting: young age at diagnosis, multiple tumours in multiple organs, familial history. Except in VHL and NF1, tumours themselves do not show specific pathological features; they usually are well differentiated and of low histological grade; their prognosis is good, except for MEN1-associated thymic NENs. The most suggestive pathological feature is their combination with various endocrine and/or non endocrine lesions in the adjacent tissue. Pathological examination is important, for a correct diagnosis and for an accurate management of the patients and their families, who must be referred to expert centers.
Asunto(s)
Síndromes Neoplásicos Hereditarios , Tumores Neuroendocrinos/patología , Neoplasias Duodenales/diagnóstico , Predisposición Genética a la Enfermedad , Humanos , Neoplasias Intestinales/complicaciones , Neoplasias Intestinales/diagnóstico , Neoplasias Intestinales/genética , Neoplasias Intestinales/patología , Intestinos/patología , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple/diagnóstico , Neoplasia Endocrina Múltiple/genética , Neoplasia Endocrina Múltiple/patología , Neoplasia Endocrina Múltiple Tipo 1/complicaciones , Neoplasia Endocrina Múltiple Tipo 1/diagnóstico , Neoplasia Endocrina Múltiple Tipo 1/genética , Neoplasia Endocrina Múltiple Tipo 1/patología , Síndromes Neoplásicos Hereditarios/complicaciones , Síndromes Neoplásicos Hereditarios/diagnóstico , Síndromes Neoplásicos Hereditarios/patología , Tumores Neuroendocrinos/complicaciones , Tumores Neuroendocrinos/diagnóstico , Tumores Neuroendocrinos/genética , Páncreas/patología , Neoplasias Pancreáticas/complicaciones , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patología , Neoplasias Gástricas/complicaciones , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/genética , Neoplasias Gástricas/patología , Neoplasias Torácicas/diagnóstico , Tórax/patología , Esclerosis Tuberosa/etiología , Esclerosis Tuberosa/patología , Enfermedad de von Hippel-Lindau/complicaciones , Enfermedad de von Hippel-Lindau/diagnóstico , Enfermedad de von Hippel-Lindau/genética , Enfermedad de von Hippel-Lindau/patologíaRESUMEN
Pheochromocytomas and paragangliomas (PPGLs) are adrenal or extra-adrenal autonomous nervous system-derived tumors. Most PPGLs are benign, but approximately 15% progress with metastases (mPPGLs). mPPGLs are more likely to occur in patients with large pheochromocytomas, sympathetic paragangliomas, and norepinephrine-secreting tumors. Older subjects, those with larger tumors and synchronous metastases, advance more rapidly. Germline mutations of SDHB, FH, and possibly SLC25A11, or somatic MAML3 disruptions relate to a higher risk for metastatic disease. However, it is unclear whether these mutations predict outcome. Once diagnosed, there are no well-established predictors of outcome in mPPGLs, and aggressive tumors have few therapeutic options and limited response. High-specific activity (HSA) metaiodine-benzyl-guanidine (MIBG) is the first FDA approved treatment and shows clinical effectiveness for MIBG-avid mPPGLs. Ongoing and future investigations should involve validation of emerging candidate outcome biomarkers, including somatic ATRX, TERT, and microRNA disruptions and identification of novel prognostic indicators. Long-term effect of HSA-MIBG and the role of other radiopharmaceuticals should be investigated. Novel trials targeting molecular events prevalent in SDHB/FH mutant tumors, such as activated hypoxia inducible factor 2 (HIF2), angiogenesis, or other mitochondrial defects that might confer unique vulnerability to these tumors should be developed and initiated. As therapeutic options are anticipated to expand, multi-institutional collaborations and well-defined clinical and molecular endpoints will be critical to achieve higher success rates in improving care for patients with mPPGLs.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/etiología , Neoplasia Endocrina Múltiple/complicaciones , Paraganglioma/etiología , Feocromocitoma/etiología , Neoplasias de las Glándulas Suprarrenales/patología , Humanos , Paraganglioma/patología , Feocromocitoma/patologíaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Adulto , Dirofilariasis/diagnóstico , Oftalmopatías/parasitología , Oftalmopatías/diagnóstico , Huésped Inmunocomprometido , Neoplasia Endocrina Múltiple/complicacionesRESUMEN
Los síndromes de neoplasia endocrina múltiple (MEN), incluyen una serie de enfermedades con alteraciones genéticas que se caracterizan por la presencia de tumores que afectan a dos o más glándulas endocrinas. Son síndromes con una herencia autosómica dominante e incluyen tres patrones: MEN 1 (síndrome de Wermer), MEN 2 (que incluye MEN 2A o síndrome de Sipple y MEN 2B o síndrome de Wagenmann-Froboese) y MEN 4. Los adenomas paratiroideos y el carcinoma medular tiroideo, son los tumores más frecuentes del MEN tipo 1 y 2 respectivamente. Esos síndromes son más comunes en pacientes jóvenes, con patología de afectación bilateral, múltiple o multifocal y, sobre todo, en pacientes con antecedentes familiares. Es necesario el trabajo en equipo de endocrinólogos, cirujanos, oncólogos y radiólogos para optimizar el tratamiento de esos pacientes.
Multiple endocrine neoplasia (MEN) encompasses a serial of familial genetically disorders in wich tumors simultaneusly occur in two or more endocrine organs. MEN síndromes are autosomal-dominant disorders categorized into three main patterns: MEN 1 (Wermer syndrome), MEN 2 (includes MEN 2A o Sipple syndrome and MEN 2B o Wagenmann-Froboese syndrome) and MEN 4. Parathyroid adenomas and medullary thyroid carcinoma are the most frecuent tumors in MEN 1 and MEN 2 respectively. These entities will be suspected in younger patients, bilateral, multiple or multifocal disease and, specially, in patients with family background. Cooperation between endocrinologist, surgeons, oncologists and radiologists is pivotal for optimizing patient treatment.
Asunto(s)
Humanos , Neoplasia Endocrina Múltiple/diagnóstico por imagen , Neoplasia Endocrina Múltiple Tipo 2b/diagnóstico por imagen , Neoplasia Endocrina Múltiple Tipo 2a/diagnóstico por imagen , Neoplasia Endocrina Múltiple Tipo 1/diagnóstico por imagen , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias de las Paratiroides/diagnóstico por imagen , Enfermedades de la Hipófisis/complicaciones , Enfermedades de la Hipófisis/diagnóstico por imagen , Neoplasia Endocrina Múltiple/complicaciones , Neoplasias de la Tiroides/diagnóstico por imagen , Neoplasias de la Corteza Suprarrenal/diagnóstico por imagen , Carcinoma Corticosuprarrenal/diagnóstico por imagen , Hiperparatiroidismo Primario/diagnóstico por imagenRESUMEN
THE AIM OF THE STUDY: Evaluation of the results of surgical treatment in patients with hyperparathyroidism related to MEN syndrome MATERIALS AND METHODS: The group of three women and two men aged between 17 and 72 years ( av. 38.6) with MEN- related hyperparathyroidism within 419 patients were operated between 2010-2016. MEN1 syndrome was diagnosed in four patients and MEN2 only once. Pre- and postoperative results of PTH levels and serum calcium values were compared. RESULTS: The mean preoperative serum PTH level was 215,56 pg/ml, whereas calcium concentration was 1.40 mmol/l. Three Patients with MEN1 syndrome had three and two thirds of parathyroid gland taken, and one had a single parathyroid gland excised with biopsy of the rest glands performed. A patient with MEN2 syndrome had one parathyroid gland excised. Postoperatively, we reported decreased secretion of both PTH (a mean serum PTH concentration 6.72 pg/ml), and serum calcium concentration 1.11 mmol/l. One patient (25%) with MEN 1 developed recurrent hyperparathyroidism after five years from the surgery. The patient was reoperated. The rest of the parathyroid gland was removed with an implantation into separated muscle pockets in the anterior forearm muscles. CONCLUSIONS: 1. MEN syndrome is a rare cause of primary hyperparathyroidism. 2. Subtotal parathyroidectomy helps to bring back a normal calcium metabolism. 3. Recurrence of hyperparathyroidism in patients with MEN syndrome requires total parathyroidectomy with an autotransplantation into the anterior forearm muscles.
Asunto(s)
Hiperparatiroidismo/cirugía , Neoplasia Endocrina Múltiple/complicaciones , Glándulas Paratiroides/cirugía , Adolescente , Adulto , Anciano , Calcio/sangre , Femenino , Estudios de Seguimiento , Humanos , Hiperparatiroidismo/sangre , Hiperparatiroidismo/etiología , Masculino , Persona de Mediana Edad , Hormona Paratiroidea/sangre , Paratiroidectomía , Recurrencia , Resultado del TratamientoRESUMEN
El hiperparatiroidismo primario (HPP) es una enfermedad endocrinológica frecuente, caracterizada por una secreción excesiva de hormona paratiroidea (PTH) que produce generalmente hipercalcemia y un conjunto de manifestaciones clínicas variables. Las manifestaciones específicas son la nefrolitiasis y la osteítis fibrosa quística, que caracterizan el fenotipo clásico de la enfermedad. Sin embargo, en la actualidad la mayoría de los pacientes son diagnosticados de forma casual tras realizar una analítica de rutina. Asimismo, se ha descrito una nueva forma de presentación denominada HPP normocalcémico cuya repercusión clínica no se encuentra bien establecida. El perfil bioquímico del HPP se caracteriza por hipercalcemia y concentraciones de PTH elevadas o inapropiadamente normales. La paratiroidectomía es el único tratamiento definitivo para el HPP, aunque algunos pacientes no son candidatos a la cirugía o rechazan la intervención. El tratamiento médico con el calcimimético cinacalcet ha demostrado normalizar la calcemia en un elevado porcentaje de casos (AU)
Primary hyperparathyroidism (PHPT) is a common endocrinological process, characterized by chronic elevation of serum concentrations of calcium and parathyroid hormone (PTH). Many years ago, the most frequent forms of clinical presentation were symptomatic renal or skeletal disease with moderate or severe hypercalcemia; however, currently, most patients have few symptoms and mild hypercalcemia. A new form of presentation called normocalcemic PHPT has also been described but clinical consequences are not well established. The biochemical profile of PHPT is characterized by hypercalcemia and high or inappropriately normal PTH concentrations. Parathyroidectomy is the only definitive cure. Medical treatment with the calcimimetic cinacalcet has been shown to normalize calcemia in a high percentage of cases (AU)
Asunto(s)
Humanos , Masculino , Femenino , Hiperparatiroidismo Primario/epidemiología , Hiperparatiroidismo Primario/prevención & control , Hipercalcemia/complicaciones , Cinacalcet/uso terapéutico , Hormona Paratiroidea/uso terapéutico , Hiperparatiroidismo Primario/tratamiento farmacológico , Hiperparatiroidismo Primario/etiología , Homeostasis , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple/epidemiología , Diagnóstico DiferencialRESUMEN
While primary hyperparathyroidism (PHPT) generally represents a common endocrine disorder, being the more frequent cause of hypercalcemia in outpatients, familial forms of PHPT (FPHPT) account for no more than 2-5% of the overall PHPT. In the last decades, many technical progresses in both molecular and biochemical-radiological evaluation have been made, and substantial advancements in understanding these disorders have been reached. Differences both in the pathogenesis and clinical presentation exist among the various hyperparathyroid syndromic forms, and, since FPHPT is frequently associated to other endocrine, proliferative and/or functional disorders, as also non-endocrine tumours, with varying clinical spectrum of occurrence in each syndrome, its early clinically detection for appropriately preventing complications (i.e. kidney and bone disorders) is strictly advised. In this review, the clinical-biochemical features and diagnostic procedures of each FPHPT form will be summarized and a general overview on surgical and pharmacological approaches to FPHPT has been also considered.
Asunto(s)
Hiperparatiroidismo Primario/terapia , Enfermedades del Recién Nacido/terapia , Neoplasias Maxilomandibulares/terapia , Neoplasia Endocrina Múltiple Tipo 1/terapia , Neoplasia Endocrina Múltiple Tipo 2a/terapia , Neoplasia Endocrina Múltiple/terapia , Diagnóstico Diferencial , Técnicas de Diagnóstico Endocrino , Humanos , Hipercalcemia/diagnóstico , Hipercalcemia/etiología , Hipercalcemia/terapia , Hiperparatiroidismo Primario/complicaciones , Hiperparatiroidismo Primario/congénito , Hiperparatiroidismo Primario/diagnóstico , Enfermedades del Recién Nacido/diagnóstico , Neoplasias Maxilomandibulares/complicaciones , Neoplasias Maxilomandibulares/diagnóstico , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple/diagnóstico , Neoplasia Endocrina Múltiple Tipo 1/complicaciones , Neoplasia Endocrina Múltiple Tipo 1/diagnóstico , Neoplasia Endocrina Múltiple Tipo 2a/complicaciones , Neoplasia Endocrina Múltiple Tipo 2a/diagnóstico , SíndromeAsunto(s)
Dirofilariasis , Infecciones Parasitarias del Ojo , Adulto , Dirofilariasis/complicaciones , Dirofilariasis/diagnóstico , Infecciones Parasitarias del Ojo/inducido químicamente , Infecciones Parasitarias del Ojo/complicaciones , Humanos , Masculino , Neoplasia Endocrina Múltiple/complicaciones , EspañaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Adulto , Carcinoma/complicaciones , Neoplasias de la Corteza Suprarrenal/complicaciones , Neoplasias de la Corteza Suprarrenal/diagnóstico , Neoplasia Endocrina Múltiple/complicaciones , Neoplasia Endocrina Múltiple/diagnóstico , Adenoma/diagnóstico , Hallazgos IncidentalesRESUMEN
We often think of the lentiginoses, phacomatoses and other neurocutaneous syndromes as conditions that affect the skin and also predispose to a variety of tumors. However, we rarely think of Peutz-Jeghers syndrome (PJS), Carney complex (CNC), Cowden disease (CD), neurofibromatosis type-1 (NF-1) or tuberous sclerosis (TSC) as conditions that are multiple endocrine neoplasias (MEN). Indeed, all of these conditions predispose to a variety of endocrine tumors, in addition to many other neoplasms. On the other hand, the classic MENs, type 1 and 2 (MEN-1 and MEN-2, respectively) are almost never thought in terms of their skin manifestations. In this review, we present extensively the MEN-1, MEN-2 and PJS syndromes, and briefly refer to CD, NF-1, and TSC. CNC is discussed in another article in this journal issue.